Halozyme Therapeutics (NASDAQ:HALO) had its price objective upped by equities research analysts at Piper Sandler from $28.00 to $31.00 in a research note issued on Thursday, The Fly reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. Piper Sandler's price target suggests a potential upside of 15.63% from the stock's current price.
Several other analysts also recently commented on HALO. Citigroup increased their target price on shares of Halozyme Therapeutics from $18.00 to $26.00 and gave the company a "neutral" rating in a report on Monday, June 15th. BidaskClub upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday. ValuEngine downgraded shares of Halozyme Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, June 1st. JMP Securities increased their target price on shares of Halozyme Therapeutics from $24.00 to $34.00 and gave the company an "outperform" rating in a report on Tuesday, May 12th. Finally, Benchmark assumed coverage on shares of Halozyme Therapeutics in a report on Wednesday. They issued a "buy" rating and a $39.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. The stock currently has an average rating of "Buy" and a consensus price target of $28.73.
Halozyme Therapeutics stock opened at $26.81 on Thursday. Halozyme Therapeutics has a 1-year low of $12.71 and a 1-year high of $28.06. The firm has a market capitalization of $3.64 billion, a price-to-earnings ratio of -48.74 and a beta of 1.84. The firm's fifty day moving average price is $24.12 and its two-hundred day moving average price is $20.51. The company has a current ratio of 11.14, a quick ratio of 10.15 and a debt-to-equity ratio of 6.66.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). The business had revenue of $25.30 million during the quarter, compared to the consensus estimate of $42.96 million. Halozyme Therapeutics had a negative net margin of 48.75% and a negative return on equity of 48.92%. The firm's quarterly revenue was down 55.5% on a year-over-year basis. During the same period last year, the business posted $0.01 earnings per share. On average, research analysts forecast that Halozyme Therapeutics will post 0.75 EPS for the current year.
In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 21,387 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $23.80, for a total transaction of $509,010.60. Following the completion of the transaction, the senior vice president now owns 197,574 shares in the company, valued at $4,702,261.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.60% of the company's stock.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. boosted its position in Halozyme Therapeutics by 0.4% during the first quarter. BlackRock Inc. now owns 12,146,804 shares of the biopharmaceutical company's stock worth $218,520,000 after purchasing an additional 50,007 shares during the period. William Blair Investment Management LLC boosted its position in Halozyme Therapeutics by 3.7% during the first quarter. William Blair Investment Management LLC now owns 6,563,606 shares of the biopharmaceutical company's stock worth $118,079,000 after purchasing an additional 232,076 shares during the period. Artisan Partners Limited Partnership boosted its position in Halozyme Therapeutics by 66.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,260,496 shares of the biopharmaceutical company's stock worth $93,269,000 after purchasing an additional 2,099,753 shares during the period. JPMorgan Chase & Co. boosted its position in Halozyme Therapeutics by 5.7% during the first quarter. JPMorgan Chase & Co. now owns 4,867,887 shares of the biopharmaceutical company's stock worth $87,573,000 after purchasing an additional 263,954 shares during the period. Finally, FMR LLC boosted its position in Halozyme Therapeutics by 5.0% during the first quarter. FMR LLC now owns 2,685,575 shares of the biopharmaceutical company's stock worth $43,238,000 after purchasing an additional 127,379 shares during the period. Hedge funds and other institutional investors own 95.37% of the company's stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Article: Portfolio Manager
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks to Buy Before the Economy Reopens
Anyone who pretends they know when the economy will reopen is not telling you the truth. And more importantly, what reopening the economy is going to look like is anybody’s guess. For certain we’re not going to be seeing anything that resembles business as usual. And more likely than not, this will not be the “V-shaped” recovery that some analysts are predicting.
Restaurants may be open, but seating capacity is likely to be limited as social distancing will remain the custom. Live sports may return, but it’s not unreasonable to expect that games will be played without fans, or at least with very few fans in attendance.
And there are other considerations as well. Workers will be allowed to go back to work, but after discovering the time value of working from home will they want to. And maybe equally as important, will employers want them to come into the office?
These are fascinating scenarios that will define the post-virus, pre-vaccine economy. But as an investor, you know that there are stocks you can buy right now that will be ready to flourish when the economy reopens.
On this list, we’re not looking at theme parks or airlines. They will come around, but slowly. Instead, we’ve picked seven stocks in different sectors that stand to benefit as the economy finds its new normal.
View the "7 Stocks to Buy Before the Economy Reopens".